about
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancerStrain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileumA phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.Fucans, but not fucomannoglucuronans, determine the biological activities of sulfated polysaccharides from Laminaria saccharina brown seaweed.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancerGalectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.Prognostic relevance of LGALS3BP in human colorectal carcinoma.Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.Prognostic value of a novel circulating serum 90K antigen in breast cancer.Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic reviewCirculating autoantibodies to LGALS3BP: a novel biomarker for cancer.EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein.Long-term outcome of breast cancer patients with pathologic N3a lymph node stage.The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides.Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients.Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey.Tumor-derived microvesicles: the metastasomes.Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis.Fabric phase sorptive extraction-high performance liquid chromatography-photo diode array detection method for simultaneous monitoring of three inflammatory bowel disease treatment drugs in whole blood, plasma and urine.Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis.Role of 90K protein in asthma and TH2-type cytokine expression.Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell CarcinomaHigh expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies
P50
Q26860469-545E36BF-0F2F-4D74-8A74-D93971B764D7Q28478419-05B4D0E3-A5B0-4FAE-A34E-51EE7CEFE27DQ33374609-6B0C6904-E506-46E6-B62E-2C6DFAC10498Q33841032-EBA62032-0F56-4AA9-9E35-0E40583897E8Q34240305-9ED2B6FA-3627-482D-A655-4FBCD2DBA157Q34284302-62DA8E2C-CDC1-49B1-A6B4-E140ED83928EQ34693483-E00243DD-0BD6-4EE7-9342-332F4EE79D2EQ35143022-D523CD99-8487-4D38-84FF-B583DDD48A54Q35899039-52DF5C99-F080-42A7-BD3F-A08F3245A2D7Q35975990-8508225A-B515-4174-98E9-F552874E6F09Q35977995-74CC90E0-66D7-46B4-B048-196FC2063746Q36546612-BC82B688-7635-405D-98BB-7FC82C276AF8Q36917231-FF9A45C7-8405-40ED-B8CE-5A436D692F04Q37309845-66DE2479-4613-4C1F-948B-7B2A7F2D8ED8Q37363290-80069538-1A06-4C03-B397-59AB6E579371Q37474367-69B3AE57-5C09-4CAC-BC73-FDF576C63986Q37683512-FE6A26E9-44F8-4676-9A3C-B605C927A8B3Q37981740-708DCC51-4220-4809-9334-405EFE5AA06EQ38018403-D7412AF6-B663-4C77-8777-953E0638227CQ38677841-31322B5A-E937-400F-B2A3-5FC2EE638124Q39022501-C65B8A42-1ED1-4C6F-89FC-A496FC63F0DDQ39043844-1616CBED-B8E0-4B44-9903-8771F07135C1Q39493859-3732EE92-7948-42DA-B0C4-0F9435773EBCQ40143565-946B1F8E-5C44-4039-9DFB-F0448683BA11Q40390763-613ED489-1005-4699-A9DB-136F6D522475Q40539610-584F55D6-271E-4ABA-A7E6-51FE7E9F2C39Q40931306-8E66C449-7076-4884-B3EC-F51B78D99E6EQ41421116-7BBD0F3C-60FC-47C8-A75C-667251E06CA2Q41749360-28188D3D-A115-428B-AE4E-A1F3F3FCC13BQ43701610-857750EC-FE9D-4223-860D-F2FDD924BB30Q44221566-24A53CFF-9686-45F8-8C17-6AA1C016F208Q46988402-B9010277-4EA8-4A2F-9379-DE2E2E44C2D1Q47383021-1957ABE8-B7EA-4E30-97C0-055C30B1C2AFQ51760132-CE00EB69-3D5A-40D6-A189-176C2FB7B4CDQ51821356-03AF4F96-2F72-4E5F-ADDF-CE99C3849DD7Q53190277-C398F901-B933-475F-B4EF-C101B0FE8F82Q54050949-B54E7B9C-CF22-437C-A07D-7DD54B8C6F04Q54692161-6664237C-F230-4685-B3C0-548995988E2FQ62623846-DD3CFE5D-02AB-418F-932D-F3DBF41115C7Q63413179-EB60D1C4-DB20-47F1-9C0A-2ED947272279
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicola Tinari
@ast
Nicola Tinari
@en
Nicola Tinari
@es
Nicola Tinari
@nl
Nicola Tinari
@sl
type
label
Nicola Tinari
@ast
Nicola Tinari
@en
Nicola Tinari
@es
Nicola Tinari
@nl
Nicola Tinari
@sl
prefLabel
Nicola Tinari
@ast
Nicola Tinari
@en
Nicola Tinari
@es
Nicola Tinari
@nl
Nicola Tinari
@sl
P106
P21
P31
P496
0000-0001-8449-5407